Retatrutida 5mg

Soporte metabólico

Per vial — Research use only

Manufactured

Canada

Purity

3rd Party Tested

Form

Lyophilized

Her Biology

Metabolism Through a Female Lens

Research Highlights

Multi-Receptor Activation

Targets GLP-1, GIP, and glucagon pathways simultaneously.

Energy Balance Regulation

Studied for effects on appetite and caloric utilization.

Metabolic Efficiency

Explored for impact on glucose and lipid metabolism.

The Research

Emerging Data on Triple-Agonist Peptides

Retatrutide has been investigated in recent studies as part of a new class of multi-agonist peptides designed to address complex metabolic systems. Research has examined its effects on weight regulation, insulin sensitivity, and energy expenditure.

Findings suggest that simultaneous activation of GLP-1, GIP, and glucagon receptors may produce synergistic effects across metabolic pathways, including appetite control and fat metabolism.

While research is ongoing, this compound represents a significant shift toward multi-pathway metabolic investigation rather than single-receptor targeting.

FemmeBioLabs presents these compounds within the context of available research — with a focus on accuracy, not exaggeration.

Batch 04. Limited units available.

Research compounds produced in controlled batch runs. Current batch available while supplies last.

For Research Use Only. Not for human consumption. This product is intended solely for in vitro diagnostic and laboratory research purposes and is not approved for use in food, drugs, medical devices, or cosmetics. FemmeBioLabs products are sold exclusively to qualified researchers and research institutions for scientific research purposes. Must be 19 years of age or older to purchase. These statements have not been evaluated by any regulatory authority. This product is not intended to diagnose, treat, cure, or prevent any disease or condition.